Literature DB >> 30602360

NHLBI-Sponsored Randomized Trial of Postconditioning During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.

Jay H Traverse1,2, Cory M Swingen2, Timothy D Henry1, Jane Fox1, Yale L Wang1, Ivan J Chavez1, Daniel L Lips1, John R Lesser1, Wesley R Pedersen1, Nicholas M Burke1, Akila Pai1, Jana L Lindberg1, Ross F Garberich1.   

Abstract

RATIONALE: Postconditioning at the time of primary percutaneous coronary intervention (PCI) for ST-segment-elevation myocardial infarction may reduce infarct size and improve myocardial salvage. However, clinical trials have shown inconsistent benefit.
OBJECTIVE: We performed the first National Heart, Lung, and Blood Institute-sponsored trial of postconditioning in the United States using strict enrollment criteria to optimize the early benefits of postconditioning and assess its long-term effects on left ventricular (LV) function. METHODS AND
RESULTS: We randomized 122 ST-segment-elevation myocardial infarction patients to postconditioning (4, 30 seconds PTCA [percutaneous transluminal coronary angioplasty] inflations/deflations)+PCI (n=65) versus routine PCI (n=57). All subjects had an occluded major epicardial artery (thrombolysis in myocardial infarction=0) with ischemic times between 1 and 6 hours with no evidence of preinfarction angina or collateral blood flow. Cardiac magnetic resonance imaging measured at 2 days post-PCI showed no difference between the postconditioning group and control in regards to infarct size (22.5±14.5 versus 24.0±18.5 g), myocardial salvage index (30.3±15.6% versus 31.5±23.6%), or mean LV ejection fraction. Magnetic resonance imaging at 12 months showed a significant recovery of LV ejection fraction in both groups (61.0±11.4% and 61.4±9.1%; P<0.01). Subjects randomized to postconditioning experienced more favorable remodeling over 1 year (LV end-diastolic volume =157±34 to 150±38 mL) compared with the control group (157±40 to 165±45 mL; P<0.03) and reduced microvascular obstruction ( P=0.05) on baseline magnetic resonance imaging and significantly less adverse LV remodeling compared with control subjects with microvascular obstruction ( P<0.05). No significant adverse events were associated with the postconditioning protocol and all patients but one (hemorrhagic stroke) survived through 1 year of follow-up.
CONCLUSIONS: We found no early benefit of postconditioning on infarct size, myocardial salvage index, and LV function compared with routine PCI. However, postconditioning was associated with improved LV remodeling at 1 year of follow-up, especially in subjects with microvascular obstruction. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01324453.

Entities:  

Keywords:  magnetic resonance imaging; myocardial infarction; percutaneous coronary intervention; postconditioning; reperfusion injury

Mesh:

Year:  2019        PMID: 30602360      PMCID: PMC6417923          DOI: 10.1161/CIRCRESAHA.118.314060

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  8 in total

1.  Response by Traverse and Garberich to Letter Regarding Article, "NHLBI-Sponsored Randomized Trial of Postconditioning During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction".

Authors:  Jay H Traverse; Ross F Garberich
Journal:  Circ Res       Date:  2019-04-12       Impact factor: 17.367

2.  Vascular conditioning prevents adverse left ventricular remodelling after acute myocardial infarction: a randomised remote conditioning study.

Authors:  Ignatios Ikonomidis; Dimitrios Vlastos; Ioanna Andreadou; Maria Gazouli; Panagiotis Efentakis; Maria Varoudi; George Makavos; Alkistis Kapelouzou; John Lekakis; John Parissis; Spiridon Katsanos; Damianos Tsilivarakis; Derek J Hausenloy; Dimitrios Alexopoulos; Dennis V Cokkinos; Hans-Eric Bøtker; Efstathios K Iliodromitis
Journal:  Basic Res Cardiol       Date:  2021-02-06       Impact factor: 17.165

3.  Effects of late, repetitive remote ischaemic conditioning on myocardial strain in patients with acute myocardial infarction.

Authors:  J Ranjit Arnold; Andrew P Vanezis; Glenn C Rodrigo; Florence Y Lai; Prathap Kanagala; Sheraz Nazir; Jamal N Khan; Leong Ng; Kamal Chitkara; J Gerry Coghlan; Simon Hetherington; Nilesh J Samani; Gerald P McCann
Journal:  Basic Res Cardiol       Date:  2022-04-23       Impact factor: 12.416

4.  Ischemic postconditioning reduces infarct size and microvascular obstruction zone in acute ST-elevation myocardial infarction - a randomized study.

Authors:  Aleksander Araszkiewicz; Marek Grygier; Małgorzta Pyda; Justyna Rajewska; Michał Michalak; Sylwia Sławek-Szmyt; Maciej Lesiak
Journal:  Postepy Kardiol Interwencyjnej       Date:  2019-09-18       Impact factor: 1.426

Review 5.  Update on Cardioprotective Strategies for STEMI: Focus on Supersaturated Oxygen Delivery.

Authors:  Robert A Kloner; Jeffrey L Creech; Gregg W Stone; William W O'Neill; Daniel Burkhoff; J Richard Spears
Journal:  JACC Basic Transl Sci       Date:  2021-10-27

6.  Alterations in ACE and ACE2 Activities and Cardiomyocyte Signaling Underlie Improved Myocardial Function in a Rat Model of Repeated Remote Ischemic Conditioning.

Authors:  Beáta Bódi; Patrick M Pilz; Lilla Mártha; Miriam Lang; Ouafa Hamza; Miklós Fagyas; Petra L Szabó; Dietmar Abraham; Attila Tóth; Bruno K Podesser; Attila Kiss; Zoltán Papp
Journal:  Int J Mol Sci       Date:  2021-10-14       Impact factor: 5.923

Review 7.  Complementary Pharmacotherapy for STEMI Undergoing Primary PCI: An Evidence-Based Clinical Approach.

Authors:  Enrico Fabris; Abi Selvarajah; Annerieke Tavenier; Rik Hermanides; Elvin Kedhi; Gianfranco Sinagra; Arnoud Van't Hof
Journal:  Am J Cardiovasc Drugs       Date:  2022-03-22       Impact factor: 3.283

Review 8.  Translational issues for mitoprotective agents as adjunct to reperfusion therapy in patients with ST-segment elevation myocardial infarction.

Authors:  Hans Erik Bøtker; Hector Alejandro Cabrera-Fuentes; Marisol Ruiz-Meana; Gerd Heusch; Michel Ovize
Journal:  J Cell Mol Med       Date:  2020-01-22       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.